In this regard, authorization was given to glofitamab-gxbm (ColumviTM), a bispecific CD20-directed CD3 T-cell engager, and elranatamab (ElrexfioTM), which targets BCMA (a protein on myeloma cells) and CD3 (a protein on the immune system’s T-cells). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.